Sign Out
No dedicated clinical drug interaction studies have been conducted.
Concomitant use of strong CYP3A4 inducer might lead to lower exposure of selinexor.
No clinically significant differences in selinexor pharmacokinetics were observed when co-administered with up to 1000 mg daily dose of paracetamol.
Continue with Google